Extrahepatic manifestations of chronic viral hepatitis C
- 作者: Kryukov E.1, Cherkashin D.1, Saluhov V.1, Matjushenko K.1, Sobolev A.1, Shcherbina N.1
-
隶属关系:
- Military Medical Academy of S.M. Kirov
- 期: 卷 24, 编号 2 (2022)
- 页面: 341-352
- 栏目: Review
- URL: https://journals.rcsi.science/1682-7392/article/view/103982
- DOI: https://doi.org/10.17816/brmma103982
- ID: 103982
如何引用文章
详细
Chronic viral diseases of the liver are frequently characterized by clinical signs of intrahepatic complications. Infection caused by the hepatitis C virus should be considered as a systemic disorder associated with the frequent development of various extrahepatic complications, such as cryoglobulinemia, glomerulopathy, lymphoproliferative diseases, seronegative arthritis, type 2 diabetes mellitus, lichen planus, and late cutaneous porphyria. Often, extrahepatic complications become the main features of the clinical disease picture, forcing patients to seek medical help from various specialists and delaying diagnosis. In some cases, the treatment of extrahepatic manifestations becomes an independent, complex task, surpassing the actual treatment of chronic hepatitis C. The relationship between hepatic and extrahepatic complications of viral hepatitis C is not linear; rather, extrahepatic manifestations often outstrip the development of liver damage. The effects of hepatitis C virus on the organs and systems of the body are caused by the direct action of the virus, pathogenetically induced by the development of steatosis/steatohepatitis, and by the disruption of system regulation of hepatokines and cytokines. Treatment of chronic hepatitis C virus infection should be comprehensive and should include antiviral therapy, treatment of metabolic-associated fatty liver disease and treatment of hepatic-related disorders. Antiviral therapy with preparations of direct antiviral action allows the prevention of not only liver complications but also of many extrahepatic complications of hepatitis C virus. Comorbid states significantly increase the natural progression of chronic hepatitis C infection and vice versa: the hepatitis C virus increases the clinical manifestations of co-pathology. In the age of direct antiviral drugs, it is possible to eliminate the hepatitis C virus, but in some cases, elimination alone does not arrest the progression of liver disease.
作者简介
Evgeniy Kryukov
Military Medical Academy of S.M. Kirov
Email: evgeniy.md@mail.ru
ORCID iD: 0000-0002-8396-1936
SPIN 代码: 3900-3441
Scopus 作者 ID: 57208311867
Researcher ID: AAO-9491-2020
Doctor of Medical Sciences, Professor
俄罗斯联邦, Saint PetersburgDmitry Cherkashin
Military Medical Academy of S.M. Kirov
Email: cherkashin_dmitr@mail.ru
ORCID iD: 0000-0003-1363-6860
SPIN 代码: 2781-9507
Doctor of Medical Sciences, Professor
俄罗斯联邦, Saint PetersburgVladimir Saluhov
Military Medical Academy of S.M. Kirov
Email: vlasaluk@yandex.ru
ORCID iD: 0000-0003-1851-0941
SPIN 代码: 4531-6011
Doctor of Medical Sciences, Professor
俄罗斯联邦, Saint PetersburgKonstantin Matjushenko
Military Medical Academy of S.M. Kirov
Email: kvmat@mail.ru
ORCID iD: 0000-0002-7399-3694
SPIN 代码: 8656-9671
Candidate of Medical Sciences
俄罗斯联邦, Saint PetersburgAleksey Sobolev
Military Medical Academy of S.M. Kirov
编辑信件的主要联系方式.
Email: sobolevvmeda@rambler.ru
ORCID iD: 0000-0003-1908-7954
SPIN 代码: 3831-6584
Teacher
俄罗斯联邦, Saint PetersburgNikolaj Shcherbina
Military Medical Academy of S.M. Kirov
Email: n.shcherbina@list.ru
ORCID iD: 0000-0003-4550-1514
Candidate of Medical Sciences
俄罗斯联邦, Saint Petersburg参考
- Hanafiah KM, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333–1342. doi: 10.1002/hep.26141
- Cacoub P, Rosenthal E. Extrahepatic manifestations in chronic hepatitis C virus carriers. Lupus. 2015;24(4–5):469–482. doi: 10.1177/0961203314556140
- Chernov VS, Kozlov KV, Paltusov EP, Kuznetsov PL. Chronic hepatitis c: a review of the current literature. Ural Medical Journal. 2019. № 9. С. 85–93. (In Russ.). doi: 10.25694/URMJ.2019.09.16
- Zhdanov KV, Yaremenko MV, Kozlov KV, et al. Non-invasive diagnosis of fibrosis in patients with CHC and obesity. Journal Infectology. 2020;12(1):40–47. (In Russ.). doi: 10.22625/2072-6732-2020-12-1-40-47
- Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology. 2005;42(4):962–973. doi: 10.1002/hep.20819
- Kalinina OV. Hepatitis C virus: variability mechanisms, classification, evolution. Problems of Virology. 2015;60(5):5–10. (In Russ.).
- Galossi A, Guarisco R, Bellis L, et al. Extrahepatic manifestations of chronic HCV infection. J Gastrointestin Liver Dis. 2007;16(1):65.
- Kryukov EV, Pop VP, Rukavitsyn OA. Hematological disorders in patients with chronic hepatitis c and approaches to the treatment. Infectious Diseases: News, Opinions, Training. 2018;(3):95–101. (In Russ.). doi: 10.24411/2305-3496-2018-13014
- Kryukov EV, Pop VP, Rukavitsyn OA. Interactions between hepatitis viruses and lymphoid tissue; modern possibilities of treatment of virus-associated lymphomas. Infectious Diseases: News, Opinions, Training. 2017;(6):53–61. (In Russ.). doi: 10.24411/2305-3496-2017-00005
- Jukić LV, Kralj D. Extrahepatic Manifestations of Hepatitis C Virus Infection. In: Smolic M, Vcev A, Wu GY, editors. Update on Hepatitis C. London: IntechOpen; 2017. doi: 10.5772/intechopen.70728
- Ferri C, Sebastiani M, Giuggioli D, et al. Hepatitis C virus syndrome: A constellation of organ-and non-organ specific autoimmune disorders, B-cell non-Hodgkin’s lymphoma, and cancer. World J Hepatol. 2015;7(3):327–343. doi: 10.4254/wjh.v7.i3.327
- Cacoub P, Desbois AC, Isnard-Bagnis C, et al. Hepatitis C virus infection and chronic kidney disease: time for reappraisal. J Hepatol. 2016;65(1):S82–S94. doi: 10.1016/j.jhep.2016.06.011
- Kuna L, Jakab J, Smolic R, et al. HCV Extrahepatic Manifestations. J Clin Transl Hepatol. 2019;7(2):172–182. doi: 10.14218/JCTH.2018.00049
- Maslennikov R, Ivashkin V, Efremova I, Shirokova E. Immune disorders and rheumatologic manifestations of viral hepatitis. World J Gastroenterol. 2021;27(18):2073–2089. doi: 10.3748/wjg.v27.i18.2073
- Adinolfi LE, Rinaldi L, Guerrera B, et al. NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations. Int J Mol Sci. 2016;17(6):803. doi: 10.3390/ijms17060803
- Fouad Y, Waked I, Bollipo S, et al. What’s in a name? Renaming NAFLD to MAFLD. Liver International. 2020;40(6):1254–1261. doi: 10.1111/liv.14478
- Eslam M, Sanyal AJ, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999–2014. doi: 10.1053/j.gastro.2019.11.312
- Perumpail BJ, Khan MA, Yoo ER, et al. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol. 2017;23(47):8263–8276. doi: 10.3748/wjg.v23.i47.8263
- Zhdanov KV, Karyakin SS, Kozlov KV, et al. Chronic hepatitis С and non-alcoholic fatty liver disease. Main aspects of pathogenesis. Bulletin of the Russian Military Medical Academy. 2018;20(1): 216–2211. (In Russ.). doi: 10.17816/brmma12326
- Wang F, So K-F, Xiao J, Wang H. Organ-organ communication: The liver’s perspective. Theranostics. 2021;11(7):3317–3330. doi: 10.7150/thno.55795
- Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med. 1992;327: 1490–1495. doi: 10.1056/NEJM199211193272104
- Misiani R, Bellavita P, Fenili D, et al. Hepatitis C Virus Infection in Patients with Essential Mixed Cryoglobulinemia. Ann Intern Med. 1992;117(7):573–577. doi: 10.7326/0003-4819-117-7-573
- Ferri C, Ramos-Casals M, Zignego AL, et al. International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. Autoimmun Rev. 2016;15(12):1145–1160. doi: 10.1016/j.autrev.2016.09.006
- Damoiseaux J. The diagnosis and classification of the cryoglobulinemic syndrome. Autoimmun Rev. 2014;13(4–5):359–362. doi: 10.1016/j.autrev.2014.01.027
- Muchtar E, Magen H, Gertz MA. How I treat cryoglobulinemia. Blood. 2017;129(3):289–298. doi: 10.1182/blood-2016-09-719773
- Dammacco F, Sansonno D. Therapy for hepatitis C virus-related cryoglobulinemic vasculitis. N Engl J Med. 2013;369:1035–1045. doi: 10.1056/NEJMra1208642
- Perez S, Kaspi A, Domovitz T, et al. Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals. PLoS Genetics. 2019;15(6):e1008181. doi: 10.1371/journal.pgen.1008181
- Adinolfi LE, Zampino R, Restivo L, et al. Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms. World J Gastroenterol. 2014;20(13):3410. doi: 10.3748/wjg.v20.i13.3410
- Morozova TS. Kliniko-patogeneticheskie podkhody k prognozirovaniyu kardiovaskulyarnykh oslozhnenii u patsientov s khronicheskimi virusnymi zabolevaniyami pecheni [dissertation abstract]. Yekaterinburg, 2021. 50 p. (In Russ.).
- Alavi M, Law MG, Valerio H, et al. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia. J Hepatol. 2019;71(2):281–288. doi: 10.1016/j.jhep.2019.04.014
- Shengir M, Elgara M, Sebastiani G. Metabolic and cardiovascular complications after virological cure in hepatitis C: What awaits beyond. World J Gastroenterol. 2021;27(17):1959–1972. doi: 10.3748/wjg.v27.i17.1959
- Manns MP, Buti M, Gane E, et al. Hepatitis C virus infection. Nature Reviews Disease Primers. 2017;3:17006. doi: 10.1038/nrdp.2017.6
- Lazebnik LB, Golovanova EV, Turkina SV, et al. Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third version. Experimental and Clinical Gastroenterology. 2021;1(1):4–52. (In Russ.). doi: 10.31146/1682-8658-ecg-185-1-4-52
- Frosi A. Extrahepatic Manifestations of Hepatitis C Infection. In: Rodrigo L, Martins I, Guo X, Qi X, editors. Advances in Hepatology. London: IntechOpen, 2021. doi: 10.5772/intechopen.95995
- Zhdanov KV, Kozlov KV, Sukachev VS, Zhabrov SS. Real-world clinical practice and future prospects of interferon-free therapy in patients with chronic hepatitis C (genotype 1). Infectious Diseases. 2018;16(2):98–103. (In Russ.). doi: 10.20953/1729-9225-2018-2-98-10